REMIMAZOLAM VS. PROPOFOL IN SEDATION FOR OUTPATIENT PROCEDURES

Sedation in outpatient procedures requires agents with a favorable pharmacokinetic profile, cardiovascular safety, and rapid recovery. Propofol, traditionally used, is effective but can cause hypotension and respiratory depression. Remimazolam, an ultra-short-acting benzodiazepine, emerges as a promising alternative, combining controllable sedation with an improved safety profile. This study aimed to compare the efficacy, safety, and recovery time of remimazolam versus propofol in patients undergoing outpatient procedures, to assess its clinical feasibility as a substitute or complement to propofol. This is a literature review with a qualitative and exploratory approach. The selection of studies was performed by consulting the PubMed, SciELO, ScienceDirect, and Scopus databases, considering full articles published in peer-reviewed scientific journals that analyze aspects related to the use of remimazolam and propofol in outpatient procedures. The time frame considered publications between 2020 and 2023, based on the oldest articles (da Silva, 2020; Melo, 2020; Rodrigues et al., 2020) and the most recent (Gomes et al., 2023; Carvalho et al., 2023). The data analyzed showed that remimazolam has sedative efficacy comparable to propofol, but with a lower incidence of hypotension, bradycardia, and respiratory depression. In addition, it showed greater predictability in recovery, especially in the elderly and patients with comorbidities. The time to cognitive function recovery and hospital discharge was similar between groups, with a slight advantage for remimazolam in some studies. Its reversibility with flumazenil also offers an additional margin of safety. It is concluded that remimazolam is a safe and effective alternative to propofol for sedation in outpatient procedures, with advantages in specific risk profiles. Despite its higher costs, its use may be preferred in vulnerable populations or in protocols that require rapid recovery and less hemodynamic instability.

Authors

Institutions

Publication Details

Journal
Health and Society
Published
2025-06-06
DOI
https://doi.org/10.51249/hs.v5i03.2544
Primary Topic
Anesthesia and Sedative Agents
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

REMIMAZOLAM VS. PROPOFOL IN SEDATION FOR OUTPATIENT PROCEDURES

Flávia Barbosa Pardini dos Santos, Iara Viana Vidigal Santana, G. Pinto, João Pedro do Valle Varela et al.
Health and Society
Anesthesia and Sedative Agents
article

REMIMAZOLAM VS. PROPOFOL IN SEDATION FOR OUTPATIENT PROCEDURES

Flávia Barbosa Pardini dos Santos, Iara Viana Vidigal Santana, G. Pinto, João Pedro do Valle Varela, Karen Sayuri Louvain de Azevedo, Ana Oliveira, Mónica Jerónimo, Lisiane Marques Cândido Pales, Aline Benício De Almeida Rochedo, Adriana dos Santos Lima, Ana Paula Pereira Maltez, Ana Laura Maruschi, Rayan Lima Beninato, Ricardo Figueiredo Porto
article en

Abstract

Sedation in outpatient procedures requires agents with a favorable pharmacokinetic profile, cardiovascular safety, and rapid recovery. Propofol, traditionally used, is effective but can cause hypotension and respiratory depression. Remimazolam, an ultra-short-acting benzodiazepine, emerges as a promising alternative, combining controllable sedation with an improved safety profile. This study aimed to compare the efficacy, safety, and recovery time of remimazolam versus propofol in patients undergoing outpatient procedures, to assess its clinical feasibility as a substitute or complement to propofol. This is a literature review with a qualitative and exploratory approach. The selection of studies was performed by consulting the PubMed, SciELO, ScienceDirect, and Scopus databases, considering full articles published in peer-reviewed scientific journals that analyze aspects related to the use of remimazolam and propofol in outpatient procedures. The time frame considered publications between 2020 and 2023, based on the oldest articles (da Silva, 2020; Melo, 2020; Rodrigues et al., 2020) and the most recent (Gomes et al., 2023; Carvalho et al., 2023). The data analyzed showed that remimazolam has sedative efficacy comparable to propofol, but with a lower incidence of hypotension, bradycardia, and respiratory depression. In addition, it showed greater predictability in recovery, especially in the elderly and patients with comorbidities. The time to cognitive function recovery and hospital discharge was similar between groups, with a slight advantage for remimazolam in some studies. Its reversibility with flumazenil also offers an additional margin of safety. It is concluded that remimazolam is a safe and effective alternative to propofol for sedation in outpatient procedures, with advantages in specific risk profiles. Despite its higher costs, its use may be preferred in vulnerable populations or in protocols that require rapid recovery and less hemodynamic instability.

Health and SocietyVol. 5(03)
Universidade do Oeste Paulista (BR), Universidade Federal do Sul da Bahia (BR), Centro Universitário Central Paulista (BR), Universidade Vila Velha (BR), Fundação Técnico Educacional Souza Marques (BR), Faculdade Estácio de Alagoas
Openalex Percentile: Top 77%
Anesthesia and Sedative Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.